Indoleamine 2,3-dioxgenase-transfected mesenchymal stem cells suppress heart allograft rejection by increasing the production and activity of dendritic cells and regulatory T cells
Restricted accessResearch articleFirst published online March, 2020
Indoleamine 2,3-dioxgenase-transfected mesenchymal stem cells suppress heart allograft rejection by increasing the production and activity of dendritic cells and regulatory T cells
Expression of indoleamine 2,3-dioxygenase (IDO) in mesenchymal stem cells (MSC) is thought to contribute to MSC-mediated immunosuppression. A lentiviral-based transgenic system was used to generate bone marrow stem cells (BMSC) which stably expressed IDO (IDO-BMSCs). Coculture of IDO-BMSCs with dendritic cells (DC) or T cells was used to evaluate the immunomodulatory effect of IDO-BMSCs. A heterotopic heart transplant model in rats was used to evaluate allograft rejection after IDO-BMSC treatment. Mechanisms of IDO-BMSC-mediated immunosuppression were investigated by evaluating levels of proinflammatory and anti-inflammatory cytokines, and production of Tregs. A significant decrease in DC marker-positive cells and a significant increase in Tregs were observed in IDO-BMSC cocultured. Treatment of transplanted rats with IDO-BMSCs was associated with significantly prolonged graft survival. Compared with the control groups, transplanted animals treated with IDO-BMSCs had a (1) significantly higher ejection fraction and fractional shortening, (2) significantly lower expression of CD86, CD80, and MHCII, and significantly higher expression in CD274, and Tregs, and (3) significantly higher levels of interleukin-10 (IL-10), transforming growth factor beta-1 (TGF-β1), TGF-β2, and TGF-β3, and significantly lower levels of IL-2 and interferon gamma. Our results expand our understanding of the molecular mechanisms underlying suppression of heart allograft rejection via IDO-expressing BMSCs.
SaidiRF, Hejazii KenariSK. Clinical transplantation and tolerance: are we there yet?Int J Organ Transplant Med2014;5:137–45.
2.
ToldoS, QuaderM, SalloumF, . Targeting the innate immune response to improve cardiac graft recovery after heart transplantation: implications for the donation after cardiac death. Int J Mol Sci2016;17:958–E958.doi:10.3390/ijms17060958
3.
LaRosaDF, RahmanAH, TurkaLA. The innate immune system in allograft rejection and tolerance. J Immunol2007;178:7503–9.doi:10.4049/jimmunol.178.12.7503
4.
YangS-H, ParkM-J, YoonI-H, . Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med2009;41:315–24.doi:10.3858/emm.2009.41.5.035
5.
GarakaniR, SaidiRF. Recent progress in cell therapy in solid organ transplantation. Int J Organ Transplant Med2017;8:125–31.
GaoF, ChiuSM, MotanDAL, . Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis2016;7:e2062.doi:10.1038/cddis.2015.327
8.
DominiciM, Le BlancK, MuellerI, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement. Cytotherapy2006;8:315–7.doi:10.1080/14653240600855905
9.
BartholomewA, SturgeonC, SiatskasM, . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol2002;30:42–8.doi:10.1016/S0301-472X(01)00769-X
10.
RingdénO, UzunelM, RasmussonI, . Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation2006;81:1390–7.doi:10.1097/01.tp.0000214462.63943.14
11.
CasiraghiF, AzzolliniN, CassisP, . Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol2008;181:3933–46.doi:10.4049/jimmunol.181.6.3933
12.
GeW, JiangJ, ArpJ, . Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation2010;90:1312–20.doi:10.1097/TP.0b013e3181fed001
13.
TseWT, PendletonJD, BeyerWM, . Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation2003;75:389–97.doi:10.1097/01.TP.0000045055.63901.A9
14.
KramperaM, GlennieS, DysonJ, . Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood2003;101:3722–9.doi:10.1182/blood-2002-07-2104
EnglishK, RyanJM, TobinL, . Cell contact, prostaglandin E 2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25 High forkhead box P3 + regulatory T cells. Clin Exp Immunol2009;156:149–60.doi:10.1111/j.1365-2249.2009.03874.x
17.
MellorAL, MunnDH. Ido expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol2004;4:762–74.doi:10.1038/nri1457
18.
HwuP, DuMX, LapointeR, . Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol2000;164:3596–9.doi:10.4049/jimmunol.164.7.3596
19.
MellorAL, LemosH, HuangL. Indoleamine 2,3-dioxygenase and tolerance: where are we now?Front Immunol2017;8.doi:10.3389/fimmu.2017.01360
20.
HeY, ZhouS, LiuH, . Indoleamine 2, 3-Dioxgenase transfected mesenchymal stem cells induce kidney allograft tolerance by increasing the production and function of regulatory T cells. Transplantation2015;99:1829–38.doi:10.1097/TP.0000000000000856
21.
LiC, LiuT, ZhaoN, . Dendritic cells transfected with indoleamine 2,3-dioxygenase gene suppressed acute rejection of cardiac allograft. Int Immunopharmacol2016;36:31–8.doi:10.1016/j.intimp.2016.03.048
22.
MeirellesLdaS, NardiNB. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol2003;123:702–11.doi:10.1046/j.1365-2141.2003.04669.x
23.
OnoK, LindseyES. Improved technique of heart transplantation in rats. Transplantation1969;8:294.
24.
NakaoA, KaczorowskiDJ, WangY, . Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Heart Lung Transplant2010;29:544–53.
25.
BendenC, GoldfarbSB, EdwardsLB, . The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric lung and heart-lung transplantation report–2014; focus theme: retransplantation. J Heart Lung Transplant2014;33:1025–33.doi:10.1016/j.healun.2014.08.005
26.
GeW, JiangJ, BarojaML, . Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant2009;9:1760–72.doi:10.1111/j.1600-6143.2009.02721.x
27.
EggenhoferE, RennerP, SoederY, . Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol2011;25:141–7.doi:10.1016/j.trim.2011.06.002
28.
WuS-M, ZhangW-X, WangM-H, . Proteomic analysis of the immunosuppressive effects of mesenchymal stem cells in a rat heart transplantation model. Adv Clin Exp Med2013;22:785–94.
29.
RenG, SuJ, ZhangL, . Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells2009;27:1954–62.doi:10.1002/stem.118
30.
Khosravi-MaharlooeiM, PakyariM, JaliliRB, . Intraperitoneal injection of IDO-expressing dermal fibroblasts improves the allograft survival. Clin Immunol2017;174:1–9.doi:10.1016/j.clim.2016.10.012
31.
NaN, LuoY, ZhaoD, . Prolongation of kidney allograft survival regulated by indoleamine 2, 3-dioxygenase in immature dendritic cells generated from recipient type bone marrow progenitors. Mol Immunol2016;79:22–31.doi:10.1016/j.molimm.2016.09.005
AmarnathS, CostanzoCM, MariottiJ, . Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol2010;8:e1000302.doi:10.1371/journal.pbio.1000302
34.
Furuzawa-CarballedaJ, LimaG, SimancasP, . Peripheral regulatory cells immunophenotyping in kidney transplant recipients with different clinical profiles: a cross-sectional study. J Transplant2012;2012:256960doi:10.1155/2012/256960
35.
JiangX-X, ZhangY, LiuB, . Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood2005;105:4120–6.doi:10.1182/blood-2004-02-0586
36.
PericoN, CasiraghiF, IntronaM, . Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol2011;6:412–22.doi:10.2215/CJN.04950610
37.
GuoK, IkeharaS, MengX. Mesenchymal stem cells for inducing tolerance in organ transplantation. Front Cell Dev Bio2014;2.doi:10.3389/fcell.2014.00008
38.
ChenC, HouJ. Mesenchymal stem cell-based therapy in kidney transplantation. Stem Cell Res Ther2016;7.doi:10.1186/s13287-016-0283-6
39.
PierógJ, TamoL, FakinR, . Bone marrow stem cells modified with human interleukin 10 attenuate acute rejection in rat lung allotransplantation. Eur J Cardiothorac Surg2018;53:194–200.doi:10.1093/ejcts/ezx257
40.
KappJA, HonjoK, KappLM, . Tcr transgenic CD8+ T cells activated in the presence of TGFbeta express FOXP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol2006;18:1549–62.doi:10.1093/intimm/dxl088
41.
YagiH, Soto-GutierrezA, ParekkadanB, . Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant2010;19:667–79.doi:10.3727/096368910X508762
42.
UllahM, LiuDD, ThakorAS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience2019;15:421–38.doi:10.1016/j.isci.2019.05.004
43.
PonteAL, MaraisE, GallayN, . The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells2007;25:1737–45.doi:10.1634/stemcells.2007-0054
